CDTX - Cidara Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CDTX is currently covered by 6 analysts with an average price target of $125.37. This is a potential upside of $19.75 (18.7%) from yesterday's end of day stock price of $105.62.

Cidara Therapeutics's activity chart (see below) currently has 27 price targets and 56 ratings on display. The stock rating distribution of CDTX is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 50.91% with an average time for these price targets to be met of 69.15 days.

Highest price target for CDTX is $173, Lowest price target is $35, average price target is $102.

Most recent stock forecast was given by ROY BUCHANAN from JMP on 03-Oct-2025. First documented stock forecast 11-May-2015.

Currently out of the existing stock ratings of CDTX, 27 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$173

$59.95 (53.03%)

$59

13 days ago
(03-Oct-2025)

6/7 (85.71%)

$71.01 (69.62%)

47

Buy

$167

$53.95 (47.72%)

$68

21 days ago
(25-Sep-2025)

4/5 (80%)

$82.24 (97.03%)

103

Buy

$100

$-13.05 (-11.54%)

$54

22 days ago
(24-Sep-2025)

9/9 (100%)

$11.42 (12.89%)

98

Buy

$35

$-78.05 (-69.04%)

$34

4 months 23 days ago
(23-May-2025)

2/2 (100%)

$10.72 (44.15%)

112

Buy

$35

$-78.05 (-69.04%)

$24

7 months 6 days ago
(10-Mar-2025)

5/17 (29.41%)

$12.61 (56.32%)

94

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CDTX (Cidara Therapeutics) average time for price targets to be met?

On average it took 69.15 days on average for the stock forecasts to be realized with a an average price target met ratio 50.91

Which analyst has the current highest performing score on CDTX (Cidara Therapeutics) with a proven track record?

ROY BUCHANAN

Which analyst has the most public recommendations on CDTX (Cidara Therapeutics)?

Roy Buchanan works at JMP and has 2 price targets and 1 ratings on CDTX

Which analyst is the currently most bullish on CDTX (Cidara Therapeutics)?

Robert Driscoll with highest potential upside - $76.06

Which analyst is the currently most reserved on CDTX (Cidara Therapeutics)?

Kevin Degeeter with lowest potential downside - -$107.05

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?